The Food and Drug Administration (FDA) has recently approved the combined use of the BRAF/MEK inhibitors, Dabrafenib and Trametinib, as a treatment for patients with BRAF V600E–positive solid tumours who have no suitable alternative treatment options.
This combination treatment has demonstrated to induce an overall response rate of up to 80% in multiple rare BRAF-positive tumour types, including gliomas, biliary tract, gynaecologic, and gastrointestinal cancers. Approval of these drugs is supported by several clinical trials, such as the phase 2 ROAR trial (NCT02034110) and the NCI-MATCH (NCT02465060) Subprotocol H study.
Australian patients with BRAF V600-positive rare cancers may be eligible for clinical trials of BRAF/MEK inhibitors or similar investigational drugs on clinical trials, including MoST sub-study 12 (vemurafenib and combimetinib). The Australian Rare Cancer Portal can assist with identifying the most relevant clinical trial near you.